125-53-1

125-53-1 structure

Name: oxyphencyclimine
Chemical Name: (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
CAS Number: 125-53-1
Molecular Formula: C₂₀H₂₈N₂O₃
Molecular Weight: 344.44800
Catalog: Signaling Pathways GPCR/G Protein mAChR
Create Date: 2016-07-10 03:26:44
Modify Date: 2024-01-05 18:54:49
Oxyphencyclimine is an orally active muscarinic receptor (mAChR) antagonist. Oxyphencyclimine is effective in reducing ulceration index and increasing pepsin activity in rat gastric ulcer model. Oxyphencyclimine can be used in studies of peptic ulcer disease and gastrointestinal spasm[1][2].

Name	(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
Synonyms	cyclohexyl-hydroxy-phenyl-acetic acid-(1-methyl-1,4,5,6-tetrahydro-pyrimidin-2-ylmethyl ester) 1-methyl-5,6-dihydro-4H-pyrimidin-2-ylmethyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Antulcus Daricol Naridan Oxyphencycliminum Oxiphencycliminum Oxyphencycliminum [INN-Latin] Cyclohexyl-hydroxy-phenyl-essigsaeure-(1-methyl-1,4,5,6-tetrahydro-pyrimidin-2-ylmethylester) Oxifencicliminum Caridan Manir

Description	Oxyphencyclimine is an orally active muscarinic receptor (mAChR) antagonist. Oxyphencyclimine is effective in reducing ulceration index and increasing pepsin activity in rat gastric ulcer model. Oxyphencyclimine can be used in studies of peptic ulcer disease and gastrointestinal spasm[1][2].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> mAChR Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> mAChR
In Vivo	Oxyphencyclimine (10 mg/kg; p.o.; single) reduces ulceration index and increases pepsin activity in rat gastric ulcer model[1]. Animal Model: Male or female Sprague-Dawley rats (160-170 g; Reserpine or Phenylbutazone-induced rat gastric ulcer model)[1]. Dosage: 10 mg/kg Administration: Oral administration; single. Result: Increased pepsin activity in Reserpine-induced gastric ulcer rat from 5.9% (1 % homogenate) and 9.0% (supernatant) to 9.7% and 18.4%, respectively. Increased pepsin activity in Phenylbutazone-induced gastric ulcer rat from 13.0% (1 % homogenate) and 26.1% (supernatant) to 21.3% and 43.6%, respectively. Decreased rate of ulcers in Reserpine and Phenylbutazone-induced rat gastric ulcer model from 93% and 100 % to 38% and 60%, respectively.